The UK drugmaker AstraZeneca has agreed to acquire Belgian cell therapy developer EsoBiotec for up to $1bn to enhance its cancer treatment capabilities. Read more.

AstraZeneca has recently been investing heavily in the cell therapy space, including two acquisitions for TeneoTwo and ...

In a report released today, Rajan Sharma from Goldman Sachs maintained a Buy rating on AstraZeneca (AZN – Research Report), with a price target ...

Recent health news highlights include Bayer's optimism over Georgia's new law against glyphosate litigation, AstraZeneca's $1 ...

The UK's FTSE 100 index increased slightly, aided by energy and metal mining sectors, as investors anticipated central bank ...

By Chandini Monnappa (Reuters) -Drugmaker AstraZeneca has agreed to buy Belgium-based biotechnology firm EsoBiotec for up to ...

AstraZeneca's eneboparatide met its Phase 3 trial goal for chronic hypoparathyroidism, while the EU approved Imfinzi for ...

AstraZeneca, headquartered in Cambridge, could pay up to $1 billion on a cash and debt-free basis for Belgian company ...

UBS analyst Matthew Weston maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £142.00. The ...

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. The deal will see AstraZeneca scoop up all ...

A phase 3 trial of AstraZeneca’s $800 million rare disease candidate has met its primary endpoint. The update keeps ...

Warren Buffett's Berkshire Hathaway (BRK-B) has increased its stakes in Japan's largest trading houses, according to reports.